Business
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Haduvio met the primary endpoint with a statistically-significant reduction
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Haduvio met the primary endpoint with a statistically-significant reduction (p","length":111,"tagName":"div"}]